HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Mercury Laboratories Ltd Stock Comparison

Cohance Lifesciences Ltd vs Mercury Laboratories Ltd Stock Comparison

Last Updated on: May 27, 2025

Key Highlights

  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1092 as of 27 May 15:30.
  • The P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 yearsThe P/E Ratio of Mercury Laboratories Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 yearsThe Market Cap of Mercury Laboratories Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Suven Pharmaceuticals Ltd for the Dec '24 is ₹ 322.86 crore as compare to the Sep '24 revenue of ₹ 271.84 crore. This represent the growth of 18.77% The revenue of Mercury Laboratories Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Suven Pharmaceuticals Ltd for the Dec '24 is ₹ 133.41 crore as compare to the Sep '24 ebitda of ₹ 118.13 crore. This represent the growth of 12.93% The ebitda of Mercury Laboratories Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 83.29 crore over 7 quarters. This represents a CAGR of -19.06% The net profit of Mercury Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Mercury Laboratories Ltd changed from 7.43 % on March 2020 to 7.43 % on March 2024 . This represents a CAGR of 0.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Mercury Laboratories Ltd

  • Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962.
  • Subsequently, the Company converted into Private Limited Company & incorporated in February, 1982.
  • Later, it further converted into Limited Company in 1992 in Maharashtra.
  • The Company is engaged in the business of Pharmaceutical items, medicinal drugs and formulations.
  • It is a profit making and dividend paying public limited company.

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

Mercury Laboratories Ltd News Hub

News

Board of Mercury Laboratories recommends final dividend

Mercury Laboratories announced that the Board of Directors of the Company at its meeting h...

Read more

14 May 2025 17:14

News

Mercury Laboratories schedules AGM

Mercury Laboratories announced that the 44th Annual General Meeting(AGM) of the company wi...

Read more

14 May 2025 17:14

News

Mercury Laboratories to announce Quarterly Result

Mercury Laboratories will hold a meeting of the Board of Directors of the Company on 14 Ma...

Read more

08 May 2025 15:24

News

Mercury Laboratories to table results

Mercury Laboratories will hold a meeting of the Board of Directors of the Company on 12 Fe...

Read more

07 Feb 2025 10:22

News

Mercury Laboratories schedules board meeting

Mercury Laboratories will hold a meeting of the Board of Directors of the Company on 14 No...

Read more

07 Nov 2024 16:57

News

Mercury Laboratories schedules AGM

Mercury Laboratories announced that the 43th Annual General Meeting (AGM) of the company w...

Read more

25 Jul 2024 14:42

SWOT Analysis Of Mercury Laboratories Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Mercury Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Suven Pharmaceuticals Ltd and Mercury Laboratories Ltd

Which company has a larger market capitalization, Suven Pharmaceuticals Ltd or Mercury Laboratories Ltd?

Market cap of Suven Pharmaceuticals Ltd is 27,815 Cr while Market cap of Mercury Laboratories Ltd is 100 Cr

What are the key factors driving the stock performance of Suven Pharmaceuticals Ltd and Mercury Laboratories Ltd?

The stock performance of Suven Pharmaceuticals Ltd and Mercury Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Pharmaceuticals Ltd and Mercury Laboratories Ltd?

As of May 27, 2025, the Suven Pharmaceuticals Ltd stock price is INR ₹1092.65. On the other hand, Mercury Laboratories Ltd stock price is INR ₹838.95.

How do dividend payouts of Suven Pharmaceuticals Ltd and Mercury Laboratories Ltd compare?

To compare the dividend payouts of Suven Pharmaceuticals Ltd and Mercury Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions